BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10481530)

  • 1. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
    Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
    Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum anti-p53 antibodies and CEA in monitoring of recurrences of colorectal cancer].
    Bielicki D; Sulzyc-Bielicka V; Domagała W
    Ann Acad Med Stetin; 2008; 54(3):99-104. PubMed ID: 19839520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
    Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
    Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
    Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
    Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
    Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
    Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
    Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical significance of serum anti-p53 antibody as a monitoring marker in colorectal cancer].
    Amano K; Kumamoto K; Kuwabara K; Ishiguro T; Ohsawa T; Okada N; Kumagai Y; Baba H; Ishibashi K; Tsuji Y; Haga N; Ishida H
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2170-2. PubMed ID: 23268013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of postoperative survival by preoperative serum concentrations of anti-p53 compared to CEA, CA 50, CA 242 and conventional blood tests in patients with colorectal carcinoma.
    Forslund A; Engarås B; Lönnroth C; Lundholm K
    Int J Oncol; 2002 May; 20(5):1013-8. PubMed ID: 11956598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of high p53 levels in colorectal cancer: a favourable prognostic factor.
    Adrover E; Maestro ML; Sanz-Casla MT; del Barco V; Cerdán J; Fernández C; Balibrea JL
    Br J Cancer; 1999 Sep; 81(1):122-6. PubMed ID: 10487622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
    Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
    Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
    Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
    Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
    Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
    Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer.
    Albanopoulos K; Armakolas A; Konstadoulakis MM; Leandros E; Tsiompanou E; Katsaragakis S; Alexiou D; Androulakis G
    Am J Gastroenterol; 2000 Apr; 95(4):1056-61. PubMed ID: 10763959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
    Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
    Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.